Organogenesis (ORGO) Set to Announce Quarterly Earnings on Tuesday

Organogenesis (NASDAQ:ORGOGet Rating) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, May 10th. Analysts expect Organogenesis to post earnings of $0.05 per share for the quarter. Organogenesis has set its FY 2022 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Organogenesis (NASDAQ:ORGOGet Rating) last posted its quarterly earnings results on Tuesday, March 1st. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.33. The company had revenue of $128.56 million for the quarter, compared to the consensus estimate of $124.35 million. Organogenesis had a return on equity of 50.66% and a net margin of 20.28%. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of NASDAQ:ORGO opened at $6.67 on Tuesday. The stock has a fifty day simple moving average of $7.56 and a two-hundred day simple moving average of $8.66. The stock has a market capitalization of $858.86 million, a price-to-earnings ratio of 9.53 and a beta of 1.71. Organogenesis has a 12-month low of $6.23 and a 12-month high of $23.99. The company has a current ratio of 2.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.29.

In other Organogenesis news, VP Antonio S. Montecalvo sold 97,436 shares of the business’s stock in a transaction dated Thursday, March 10th. The stock was sold at an average price of $8.39, for a total transaction of $817,488.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 34.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in ORGO. Royal Bank of Canada lifted its position in shares of Organogenesis by 25.9% in the second quarter. Royal Bank of Canada now owns 4,179 shares of the company’s stock worth $69,000 after buying an additional 861 shares in the last quarter. Guggenheim Capital LLC purchased a new stake in shares of Organogenesis in the fourth quarter worth about $250,000. Cubist Systematic Strategies LLC raised its position in Organogenesis by 92.3% during the fourth quarter. Cubist Systematic Strategies LLC now owns 35,665 shares of the company’s stock valued at $330,000 after purchasing an additional 17,114 shares during the period. State of Tennessee Treasury Department raised its position in Organogenesis by 14.5% during the fourth quarter. State of Tennessee Treasury Department now owns 36,149 shares of the company’s stock valued at $334,000 after purchasing an additional 4,570 shares during the period. Finally, Barclays PLC raised its position in Organogenesis by 20.0% during the fourth quarter. Barclays PLC now owns 58,663 shares of the company’s stock valued at $543,000 after purchasing an additional 9,766 shares during the period. Institutional investors and hedge funds own 38.41% of the company’s stock.

Several research analysts have recently weighed in on the company. TheStreet upgraded Organogenesis from a “d+” rating to a “c” rating in a research note on Friday, January 7th. Zacks Investment Research cut Organogenesis from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 8th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $19.75.

Organogenesis Company Profile (Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

Further Reading

Earnings History for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.